BRIEF-U.S. FDA Approves Update To The Label For Winrevair To Include Data From The Phase 3 Hyperion Trial Evaluating Adults Recently Diagnosed With Pulmonary Arterial Hypertension

Sept 22 (Reuters) – Merck & Co Inc: * U.S. FDA APPROVES UPDATE TO THE LABEL FOR WINREVAIR™ (SOTATERCEPT-CSRK) TO INCLUDE DATA FROM THE PHASE 3 HYPERION TRIAL EVALUATING ADULTS RECENTLY DIAGNOSED WITH

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)